Kangmei Pharma | 600518 - Current Liabilities


Kangmei Pharma reported CNY5.38B in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Akebia Therapeutics USD 173.88M 10.95M Mar/2026
Alaunos Therapeutics USD 595K 218K Mar/2026
Avita Medical AUD 62.68M 77K Dec/2025
Cspc Pharmaceutical CNY 10.18B 65.36M Dec/2025
Dianthus Therapeutics USD 38.28M 7.55M Mar/2026
Genomma Lab Internacional MXN 7.65B 418.99M Mar/2026
Hypermarcas BRL 3.43B 676.7M Mar/2026
Ionis Pharmaceuticals USD 717M 66M Mar/2026
IQVIA Holdings USD 8.33B 9M Mar/2026
Jiangsu Hengrui CNY 5.64B 732.51M Mar/2026
Kangmei Pharma CNY 5.38B 433.79M Mar/2026
Moderna USD 2.4B 408M Mar/2026
Organon & Co USD 2.5B 110M Mar/2026
Revvity USD 1.24B 92.6M Mar/2026
Sh Fosun Pharma CNY 36.58B 156.4M Mar/2026
Tectonic Therapeutic USD 12.96M 3.29M Mar/2026
Viatris USD 6.81B 284M Mar/2026
Wuxi Apptec CNY 19.04B 193.78M Mar/2026
Xeris Pharmaceuticals USD 118.59M 9.02M Mar/2026
Zz Pientze Pharmaceu CNY 2.28B 134.52M Mar/2026